Abstracts tagged "Pediatric rheumatology"

Abstract Number: 0975 • ACR Convergence 2021
Data-driven MRI Definitions for Active and Structural Sacroiliac Joint Lesions in Juvenile Spondyloarthritis Typical of Axial Disease
Pamela Weiss¹, Timothy Brandon¹, Amita Aggarwal², Ruben Burgos-Vargas³, Robert Colbert⁴, Gerd Horneff⁵, Rik Joos⁶, Ronald Laxer⁷, Kirsten Minden⁸, Angelo Ravelli⁹, Nicolino Ruperto¹⁰, Judith Smith¹¹, Matthew Stoll¹², Shirley Tse⁷, Filip Van den Bosch¹³, Robert Lambert¹⁴, David Biko¹⁵, Nancy Chauvin¹⁶, Michael Francavilla¹⁵, Jacob Jaremko¹⁴, Nele Herregods¹⁷, Ozgur Kasapcopur¹⁸, Mehmet YILDIZ¹⁹, Alison Hendry²⁰ and Walter Maksymowych²¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ³Department of Rheumatology, General Hospital of Mexico, Ciudad de Mxico, Mexico, ⁴NIH/NIAMS, Bethesda, MD, ⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Sankt Augustin, Germany, ⁶Ghent University, Ghent, Belgium, ⁷SickKids, Toronto, ON, Canada, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹Istituto Giannina Gaslini, Genoa, Italy, ¹⁰IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy, ¹¹University of Wisconsin, Madison, WI, ¹²University of Alabama at Birmingham, Birmingham, AL, ¹³Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ¹⁴University of Alberta, Edmonton, AB, Canada, ¹⁵University of Pennsylvania, Philadelphia, PA, ¹⁶Penn State Health, Hershey, PA, ¹⁷Universitair Ziekenhuis Ghent, Ghent, Belgium, ¹⁸Istanbul University-Cerrahpasa, Cerrahpasa Medical School, İstanbul, Turkey, ¹⁹Istanbul University-Cerrahpasa, Faculty of Medicine, Pediatric Rheumatology, İstanbul, Turkey, ²⁰NZ Familial GI Cancer Service, Auckland, New Zealand, ²¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada
Background/Purpose: Determining optimal cut-offs for active and structural imaging lesions of juvenile spondyloarthritis (JSpA) with axial disease is important for diagnosis, therapeutic management, and classification.…
Abstract Number: 1615 • ACR Convergence 2021
Responsiveness of Quality of Life and Function Assessment to Changes in Topical Eye Medications in Children with Uveitis
Virginia Miraldi Utz¹, Amy Cassedy¹, Theresa Hennard¹, Najima Mwase² and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²University of Nevada, Las Vegas, Las Vegas, NV
Background/Purpose: Children with uveitis often require topical eye medications (eye drops) to control inflammation (glucocorticoids) and complications such as elevated intraocular pressure and synechiae (glaucoma…
Abstract Number: 1634 • ACR Convergence 2021
Patient Activation and Health Literacy in the Pediatric to Adult Transition in Juvenile Systemic Lupus Erythematosus: Patient and Health Care Team Perspectives
Ashley Ciosek¹, Una Makris², Justin Kramer³, Tracey Wright⁴ and Nicole Bitencourt⁵, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern Medical Center, Dallas Veterans Administration, Dallas, TX, ³Texas A&M University, College Station, ⁴UT Southwestern Medical Center, Children's Health, Texas Scottish Rite Hospital for Children, Plano, TX, ⁵Loma Linda University Medical Center, Redlands, CA
Background/Purpose: Advances in treatment of juvenile-onset systemic lupus erythematosus have ensured increased survival such that long-term quality of life and disease management must be considered.…
Abstract Number: 0253 • ACR Convergence 2021
Rheumatoid Factor Status as a Predictor of Disease Activity and Disability:An Analysis of the New CARRA Registry Polyarticular Juvenile Idiopathic Arthritis Cohort
Nayimisha Balmuri¹, William Soulsby², Victoria Cooley³, Linda Gerber⁴, Erica Lawson² and Karen Onel¹, ¹Hospital for Special Surgery, New York, NY, ²University of California San Francisco, San Francisco, CA, ³Weil Cornell Medicine, New York, NY, ⁴Weill Cornell Medicine, New York, NY
Background/Purpose: Children with rheumatoid factor (RF) positive polyarticular JIA (pJIA) are less likely to go into remission and more likely to develop erosive disease than…
Abstract Number: 0770 • ACR Convergence 2021
Evaluation of the Lupus Low Disease Activity State (LLDAS) vs. the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K Score in a Pediatric Systemic Lupus Erythematosus Cohort
Bridget Wilson, Tingting Qiu, Angela Merritt, Bin Huang and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease which can affect any organ system, and ongoing disease activity leads to organ damage. The…
Abstract Number: 0976 • ACR Convergence 2021
Cumulative Social Disadvantage Predicts an Arthritis Diagnosis: A Cross-sectional Analysis of the National Survey of Children’s Health (NSCH)
William Soulsby, Erica Lawson and Matthew Pantell, University of California San Francisco, San Francisco, CA
Background/Purpose: The impact of social determinants of health in juvenile idiopathic arthritis (JIA) remains poorly understood. Racial disparities exist in JIA, including increased pain and…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 1636 • ACR Convergence 2021
Pediatric Rheumatologists’ Perspectives on Diagnosis, Treatment and Outcomes of Sjögren Syndrome in Children and Adolescents
Rachel Randell¹, Sara Stern², Heather Van Mater¹, Scott Lieberman³ and Matthew Basiaga⁴, ¹Duke University, Durham, NC, ²University of Utah, Salt Lake City, UT, ³University of Iowa, Iowa City, IA, ⁴Mayo Clinic, Inver Grove Heights, MN
Background/Purpose: Sjögren syndrome in children and adolescents often presents differently from adult disease, with many pediatric patients failing to meet adult criteria. Additionally, treatment and…
Abstract Number: 0254 • ACR Convergence 2021
Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis
Elaine Flanagan¹, Rosemary Peterson², Susan Shenoi³, Helena Chang⁴, Kelly Wang⁴, Rebecca Trachtman⁴ and Karen Onel⁵, ¹Emory/CHOA, Atlanta, GA, ²Dell Children's Medical Center, Austin, TX, ³Seattle Children's Hospital, Seattle, WA, ⁴Icahn School of Medicine at Mount Sinai, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
Abstract Number: 0771 • ACR Convergence 2021
Race, Ethnicity and Patient-Reported Outcomes in Childhood-Onset Systemic Lupus Erythematosus
R. Ezequiel Borgia¹, Matthew Gurka², Stephanie Filipp², Melissa Elder³, Michelle Cardel² and Natalie Shiff⁴, ¹Department of Pediatrics, University of Florida, Gainesville, FL, USA. Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, ²Department of Health Outcomes and Biomedical Informatics, University of Florida, Gainesville, ³Division of Pediatric Allergy, Immunology and Rheumatology, Department of Pediatrics, University of Florida, Gainesville, FL, ⁴University of Saskatchewan, Department of Community Health and Epidemiology, Saskatoon, SK, Canada. Janssen Scientific Affairs, LLC, Horsham, PA., Gainesville, FL
Background/Purpose: The association of race/ethnicity with childhood-onset systemic lupus erythematosus (cSLE) outcomes has been well described, with non-White individuals experiencing a more severe disease phenotype…
Abstract Number: 0979 • ACR Convergence 2021
Autoantibody Testing in Juvenile Localized Scleroderma and Systemic Sclerosis: Comparing Antibody Profiles and Clinical Correlations
Jonathan Li¹, Emily Mirizio¹, Katherine Buhler², May Choi³, Haiyan Hou², Giffin Werner¹, Anwesha Sanyal¹, Kaila Schollaert-Fitch¹, Marvin Fritzler² and Kathryn Torok¹, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Pediatric scleroderma encompasses juvenile onset localized scleroderma (jLS) and juvenile onset systemic sclerosis (jSSc), both of which present with varied cutaneous fibrosis and systemic…
Abstract Number: 1617 • ACR Convergence 2021
Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease
Maitry Sonagra¹, Jeremy Jones², Mackenzie McGill³ and Sabrina Gmuca³, ¹Seattle Children's Hospital, Seattle, WA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Adverse childhood experiences (ACEs) serve as stressors that can have negative, lasting effects on health and wellbeing. While there has been increasing evidence to…
Abstract Number: 1637 • ACR Convergence 2021
Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience
Eric Kok, Martha Curry, Andrea Ramirez, Eyal Muscal and Marietta DeGuzman, Baylor College of Medicine, Houston, TX
Background/Purpose: Infection with novel coronavirus (COVID-19) in children, unlike adults, is generally asymptomatic or causes mild disease although some may develop severe illness. In particular,…
Abstract Number: 0714 • ACR Convergence 2020
Response to Abatacept in JIA Categories: Results from the PRCSG/PRINTO JIA Abatacept Phase IV Registry
Daniel J Lovell¹, Nikolay Tzaribachev², Esi Morgan³, Gabriele Simonini⁴, Thomas Griffin⁵, Ekaterina Alexeeva⁶, John Bohnsack⁷, Andrew Zeft⁸, Gerd Horneff⁹, Richard Vehe¹⁰, Valda Stanevicha¹¹, Stacey Tarvin¹², Maria Trachana¹³, Adam Huber¹⁴, Daniel Kietz¹⁵, Ilonka Orban¹⁶, Jason Dare¹⁷, Ivan Foeldvari¹⁸, Pierre Quartier¹⁹, Alyssa Dominique²⁰, Tzuyung Douglas Kou²⁰, Robert Wong²⁰, Alberto Martini²¹, Hermine Brunner³ and Nicolino Ruperto²², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ³Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Anna Meyer Children's Hospital, Firenze, Italy, ⁵Levine Children's Hospital, Charlotte, NC, ⁶Scientific Center of Children’s Health of RAMS, Moscow, Russia, ⁷University of Utah and Primary Children's Hospital, Cincinnati, OH, ⁸Cleveland Clinic, Cleveland, OH, ⁹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹⁰University of Minnesota, Minneapolis, MN, ¹¹Riga Stradins University, Riga, Latvia, ¹²Riley Children’s Health, Indianapolis, IN, ¹³Aristotle University of Thessaloniki, Thessaloníki, Greece, ¹⁴Dalhousie University, Halifax, NS, Canada, ¹⁵Children’s Hospital of Pittsburgh, Pittsburgh, PA, ¹⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ¹⁷University of Arkansas for Medical Sciences, Little Rock, AR, ¹⁸Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ¹⁹Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France, ²⁰Bristol-Myers Squibb Company, Princeton, NJ, ²¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ²²Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Abatacept, a selective T-cell co-stimulation modulator, has been demonstrated to be well tolerated and effective in JIA in 2 Phase III studies.1,2 The ongoing…
Abstract Number: 0937 • ACR Convergence 2020
Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Rahul Chanchlani¹, Anastasia Gayowsky², Sandeep Brar³, Elizabeth Darling⁴, Catherine Demers⁴, Tapas Mondal¹, Rulan Parekh⁵, Hsien Seow⁴ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²ICES McMaster, Hamilton, ON, Canada, ³University of California, San Fransisco, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Toronto, Toronto, Canada
Background/Purpose: Kawasaki disease (KD) is a common childhood vasculitis associated with coronary artery aneurysms (CAA). Based on our recent work, the incidence of KD has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].